NDA 011792 · Mylan Speciality Lp
Soma
Carisoprodol · Oral · Muscle Relaxant
NovelLast checked: Nov 20, 2026Latest source record: Apr 4, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Apr 9, 1959
Approved uses
2
Original approval plus efficacy supplements
Registered trials
4
4 Phase 3, 0 recruiting
FAERS reports
19,021
13,059 serious, 4,017 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 29, 2025.
SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2) ]. SOMA is a muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. (1) Limitations of Use • Should only be used for acute treatment periods up to two or three weeks (1)
Mechanism: The mechanism of action of carisoprodol in relieving discomfort associated with acute painful musculoskeletal conditions has not been clearly identified. In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 2007 Supplement 41 · Efficacy LetterReviewLabel
- Apr 9, 1959 Original approval · Type 1 - New Molecular Entity
3 products under this application
- SOMA · CARISOPRODOL 250MG · CAPSULE, ORAL · Discontinued
- SOMA · CARISOPRODOL 350MG · TABLET, ORAL · Prescription · TE AA
- SOMA · CARISOPRODOL 250MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Carisoprodol" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower BackPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00671502 · 840 participants · Start Apr 2008 · Primary completion Feb 2009
Drug: Carisoprodol SR; Carisoprodol SR and 1 more · For: Lower Back Pain
Sites: Birmingham, Alabama; Huntsville, Alabama; Montgomery, Alabama · 68 sites in all
- Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower BackPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00671879 · 830 participants · Start Apr 2008 · Primary completion Mar 2009
Drug: Carisoprodol SR 700 mg; Carisoprodol SR 500 mg and 1 more · For: Lower Back Pain
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Hueytown, Alabama · 73 sites in all
- A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+ParacetamolPivotal-lookingStatus unknown
Farmoquimica S.A.Industry
NCT01421433 · 160 participants (planned) · Start May 2012 · Primary completion Aug 2012
Drug: Tandrilax; Dolamin Flex · For: Low Back Pain
Sites: São Paulo, Brazil
- Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.Pivotal-lookingWithdrawn
Ache Laboratorios Farmaceuticos S.A.Industry
NCT03508167 · 0 participants · Start Jan 2020 · Primary completion Oct 2020
Drug: Dorilax®; Placebo · For: Low Back Pain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain1,624
- completed suicide1,459
- drug ineffective1,319
- nausea1,294
- headache1,102
- anxiety992
- depression990
- fatigue989
- toxicity to various agents917
- insomnia829
- vomiting819
- drug dependence797
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 607 |
| 2005 | 750 |
| 2006 | 601 |
| 2007 | 511 |
| 2008 | 671 |
| 2009 | 763 |
| 2010 | 1,289 |
| 2011 | 1,148 |
| 2012 | 1,433 |
| 2013 | 1,160 |
| 2014 | 978 |
| 2015 | 1,366 |
| 2016 | 1,602 |
| 2017 | 1,086 |
| 2018 | 1,085 |
| 2019 | 1,059 |
| 2020 | 1,034 |
| 2021 | 600 |
| 2022 | 354 |
| 2023 | 275 |
| 2024 | 268 |
| 2025 | 207 |
| 2026 | 173 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Soma (Carisoprodol)
2024 spending
$1.5M
Beneficiaries
237
1,511 claims
Per beneficiary
$6,192
$10.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,431,580 |
| 2021 | $1,470,409 |
| 2022 | $1,489,510 |
| 2023 | $1,547,299 |
| 2024 | $1,467,569 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4.
Miller BS, Blair JC, Rasmussen MH, et al. · Eur J Endocrinol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- The Effects of Neurodevelopmental Therapy on Feeding and Swallowing Activities in Children with Cerebral Palsy.
Acar G, Ejraei N, Turkdoğan D, et al. · Dysphagia 2022 · Randomized Controlled Trial
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM, Morden JP, Harrington KJ, et al. · Lancet Oncol 2011 · Clinical Trial, Phase III, Comparative Study
- A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury.
Cheng J, Jiang J, He B, et al. · Sci Transl Med 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Interruption of Endolysosomal Trafficking After Focal Brain Ischemia.
Hu K, Gaire BP, Subedi L, et al. · Front Mol Neurosci 2021 · Systematic Review
Sponsor: Mylan Speciality Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.